SCHEMBL1396441

SCHEMBL1396441

CCCCOC(=O)C[C@H](N)C(=O)OCCCC

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.47
ALDH1A1 P00352 1/20 0.47
NPSR1 Q6W5P4 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ATM Q13315 1/20 0.44
DGKA P23743 1/20 0.42
HTR2C P28335 1/20 0.42
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
RAD52 P43351 1/20 0.41
P2RY10 O00398 4/20 0.40
GPR34 Q9UPC5 2/20 0.40
FAAH O00519 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39
NOD1 Q9Y239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8407943 1.00 NAAA (0.47) NAAAALDH1A1NPSR1MAPTMAPK1
SCHEMBL14514324 1.00 NAAA (0.47) NAAAALDH1A1NPSR1MAPTMAPK1
Hydrochloric Acid SCHEMBL3914765 0.98 NPSR1 (0.48) NAAAALDH1A1NPSR1MAPTMAPK1
Hydrochloric Acid SCHEMBL3914767 0.98 NPSR1 (0.48) NAAAALDH1A1NPSR1MAPTMAPK1
SCHEMBL1644712 0.94 NAAA (0.55) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL472925 0.94 NAAA (0.55) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL17231345 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL9442151 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL2283336 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1
SCHEMBL2279558 0.93 NAAA (0.58) NAAANPSR1MAPTMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118240279-A Plasticizer, plastic composition and plastic product 星欧光学股份有限公司 2024-06-25 CN disclosed
US-20220015393-A1 APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2022-01-20 US disclosed
EP-3512486-B1 BLUE POWDER AND USE THEREOF IN COSMETICS OREAL (FR) 2020-10-21 EP disclosed
EP-3512486-A1 BLUE POWDER AND USE THEREOF IN COSMETICS L'Oreal (FR) 2019-07-24 EP disclosed
CN-109689010-A Blue powder and its purposes in cosmetics 莱雅公司 2019-04-26 CN disclosed
US-10167313-B2 Selective caspase inhibitors and uses thereof GENESIS TECHNOLOGIES LIMITED (BB) 2019-01-01 US disclosed
WO-2018050504-A1 BLUE POWDER AND USE THEREOF IN COSMETICS L'OREAL (FR) 2018-03-22 WO disclosed
EP-2288615-B1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF GENESIS TECH LTD (BB) 2017-06-21 EP disclosed
US-20170114092-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF GENESIS TECH LTD (BB) 2017-04-27 US disclosed
US-9562069-B2 Selective caspase inhibitors and uses thereof NEW WORLD LABORATORIES INC. (CA) 2017-02-07 US disclosed
EP-2288615-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF New World Laboratories Inc. (CA) 2011-03-02 EP disclosed
WO-2010133000-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF NEW WORLD LABORATORIES INC. (CA) 2010-11-25 WO disclosed
EP-2152320-A2 ENCAPSULATED CONTRAST AGENTS Intezyne Technologies Incorporated (US) 2010-02-17 EP disclosed
WO-2009140765-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF NEW WORLD LABORATORIES INC. (CA) 2009-11-26 WO disclosed
EP-1833958-A4 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES INC (US) 2009-01-14 EP disclosed
WO-2008134734-A2 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 WO disclosed
EP-1833958-A2 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF Intezyne Technologies Incorporated (US) 2007-09-19 EP disclosed
WO-2006074202-A2 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-07-13 WO disclosed
CN-1137888-C Inhibitors of caspases ��ʽ����LGCI 2004-02-11 CN disclosed
CN-1377344-A Inhibitor of cysteinyl aspartic acid proteinase LG CI CO LTD (KR) 2002-10-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114092-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF CASP1, CASP3, CASP5 NAAA 1645/4885ALDH1A1 2471/4885NPSR1 4236/4885
US-10167313-B2 Selective caspase inhibitors and uses thereof CASP1, CASP3, CASP5 NAAA 1645/4885ALDH1A1 2471/4885NPSR1 4236/4885
US-20220015393-A1 APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE AADAT, SLC1A5, SLC1A3 NAAA 83/4885ALDH1A1 1813/4885NPSR1 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.